Compare IONQ Inc (IONQ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Sanofi SA — how do they compare? IONQ Inc trades at $39.89 (market cap $15.98B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 6× IONQ Inc's market cap, and Sanofi SA pays a 6.01% dividend while IONQ Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Sanofi SA for 94 Days on average.
| IONQ | SNY | |
|---|---|---|
Market Cap | $15.98B | $95.18B |
Volume | 22,848,240 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $82.09 | $52.34 |
52-Week Low | $26.59 | $39.51 |
Typical Hold Time | 33 Days | 94 Days |
Enterprise Value | $13.92B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.45, down 4.57% today, with bearish technical signals from moving averages but bullish oscillators. The company shows strong revenue growth ($130M in 2025 to $246M projected for 2026) but significant losses (-$510M net income in 2025). Recent Q2 2026 earnings missed expectations, while Q1 and Q4 2025 beat. Analyst consensus is split 50/50 buy/hold with a $62.75 price target, suggesting 59% upside potential from current levels.
IONQ presents high-risk, high-reward potential with substantial revenue growth offset by deep losses and negative margins. The quantum computing sector offers long-term upside if commercialization succeeds, but investors face dilution risk from continued cash burn and execution challenges in scaling technology. Current valuation multiples (P/S 54.74) appear stretched relative to profitability metrics.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
